Search Result

Results for "

RRMs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (5) Caspase (1) Cathepsin (1) CDK (1) HBV (1) Isotope-Labeled Compounds (1) LPL Receptor (1) NF-κB (4) SARS-CoV (1) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (3) Infection (2) Inflammation/Immunology (5) Neurological Disease (3)
Oligonucleotides:	Pre-designed siRNA Sets (3) siRNAs (3)

Inhibitors & Agonists

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P0109A

Z-FA-FMK 3 Publications Verification (1S)-Z-FA-FMK	SARS-CoV Cathepsin Apoptosis Caspase	Infection Cancer
Z-FA-FMK ((1S)-Z-FA-FMK) is a potent Cathepsin B and L inhibitor. Z-FA-FMK blocks the induction of DEVDase activity, DNA fragmentation, and externalization of phosphatidylserine by selective synthetic retinoid-related molecules (RRMs). Z-FA-FMK inhibits apoptosis. Z-FA-FMK inhibits caspase activity and selectively inhibits recombinant effector caspases 2, -3, -6, and -7. Z-FA-FMK is a viral inhibitor. Z-FA-FMK inhibits reovirus replication in a susceptible host .

HY-B2116

Osalmid Oxaphenamide; 4'-Hydroxysalicylanilide	HBV	Infection
Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC₅₀ of 8.23 μM.

HY-153898

rTRD01	Others	Neurological Disease
rTRD01 is a TDP-43 ligand that binds to TDP-43’s RRM1 and RRM2 domains (K_d=89 uM for TDP-43_102–269). rTRD01 partially disrupts TDP-43’s interaction with the hexanucleotide RNA repeat of the disease-linked c9orf72 gene. rTRD01 can be used for the research of neurodegenerative diseases .

HY-112358

GW8510	CDK	Neurological Disease Cancer
GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .

HY-153736

NSC 194308	Others	Cancer
NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .

HY-13010

Laquinimod 2 Publications Verification ABR-215062	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has?the?potential?for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases?research .

HY-RS12285

RRM1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RRM1 Human Pre-designed siRNA Set A contains three designed siRNAs for RRM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RRM1 Human Pre-designed siRNA Set A RRM1 Human Pre-designed siRNA Set A

HY-RS12286

RRM2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RRM2 Human Pre-designed siRNA Set A contains three designed siRNAs for RRM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RRM2 Human Pre-designed siRNA Set A RRM2 Human Pre-designed siRNA Set A

HY-RS12287

RRM2B Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
RRM2B Human Pre-designed siRNA Set A contains three designed siRNAs for RRM2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RRM2B Human Pre-designed siRNA Set A RRM2B Human Pre-designed siRNA Set A

HY-16734

Amiselimod MT-1303	LPL Receptor	Inflammation/Immunology
Amiselimod (MT-1303) is a modulator for sphingosine 1-phosphate receptor (S1P receptor). Amiselimod converses to its active metabolite (S)-amiselimod phosphate by sphingosine kinases (SPHKs), targets S1P1 receptor, ameliorates the autoimmune disease without causing bradycardia .

HY-W062904

Laquinimod sodium ABR-215062 sodium	NF-κB Apoptosis	Neurological Disease Inflammation/Immunology
Laquinimod (ABR-215062) sodium, an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod sodium reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod sodium has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-13010S

Laquinimod-d5 ABR-215062-d₅	Isotope-Labeled Compounds Apoptosis NF-κB	Inflammation/Immunology
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

HY-13010R

Laquinimod (Standard)	NF-κB Apoptosis	Inflammation/Immunology
Laquinimod (Standard) is the analytical standard of Laquinimod. This product is intended for research and analytical applications. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator which prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Cat. No.	Product Name	Chemical Structure

HY-13010S

Laquinimod-d5
Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

Laquinimod-d5

Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research .

RRM1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
RRM1 Human Pre-designed siRNA Set A contains three designed siRNAs for RRM1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RRM2 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
RRM2 Human Pre-designed siRNA Set A contains three designed siRNAs for RRM2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

RRM2B Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
RRM2B Human Pre-designed siRNA Set A contains three designed siRNAs for RRM2B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.